Home Business Apellis or Novartis? By StockNews

Apellis or Novartis? By StockNews

© Reuters. Better Pharmaceutical Stock: Apellis or Novartis?

The pharmaceutical industry is burgeoning, owing to substantial investments and research breakthroughs and advances. Thus, pharma players Apellis (APLS) and Novartis (NVS) should benefit. But which of these stocks is a better buy now? Read more to find out.Apellis Pharmaceuticals, Inc. (NASDAQ:) is a Crestwood, Ky.-based clinical-stage biopharmaceutical company that is focused on developing therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. In comparison, Novartis AG (NVS) researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz, and is based in Switzerland.

The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments. The industry has been attracting rising investments for the development of personalized or precision drugs, and continued innovation in the industry should drive its growth in the coming years. The global pharmaceutical market is expected to reach $1.7 trillion in 2025, growing at an 8% CAGR. So, Pharma stocks, APLS and NVS are expected to benefit from the industry tailwinds.

NVS has gained 1.3% in price over the past six months, while APLS has shed 31% over the period. In addition, NVS’ 9.7% retreat year-to-date compares with APLS’ 43.7% dive. However, in terms of their past year’s performance, APLS is the clear winner with 12.4% gains versus NVS’ 5.1% slump.

Continue reading on StockNews

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.